

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) and Figure 74 (SEQ ID NO:139).

2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:3), Figure 3 (SEQ ID NO:8), Figure 5 (SEQ ID NO:10), Figure 7 (SEQ ID NO:12), Figure 9 (SEQ ID NO:14), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID NO:21), Figure 15 (SEQ ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:31), Figure 21 (SEQ ID NO:38), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:51), Figure 27 (SEQ ID NO:53), Figure 29 (SEQ ID NO:55), Figure 31 (SEQ ID NO:57), Figure 33 (SEQ ID NO:62), Figure 35 (SEQ ID NO:64), Figure 37 (SEQ ID NO:72), Figure 39 (SEQ ID NO:77), Figure 41 (SEQ ID NO:79), Figure 43 (SEQ ID NO:83), Figure 45 (SEQ ID NO:85), Figure 47 (SEQ ID NO:90), Figure 49 (SEQ ID NO:98), Figure 51 (SEQ ID NO:103), Figure 53 (SEQ ID NO:105), Figure 55 (SEQ ID NO:107), Figure 57 (SEQ ID NO:109), Figure 59 (SEQ ID NO:114), Figure 61 (SEQ ID NO:120), Figure 63 (SEQ ID NO:125), Figure 65 (SEQ ID NO:127), Figures 67A-B (SEQ ID NO:129), Figure 69 (SEQ ID NO:131), Figure 71 (SEQ ID NO:136) and Figure 73 (SEQ ID NO:138).

3. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:3), Figure 3 (SEQ ID NO:8), Figure 5 (SEQ ID NO:10), Figure 7 (SEQ ID NO:12), Figure 9 (SEQ ID NO:14), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID NO:21), Figure 15 (SEQ ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:31), Figure 21 (SEQ ID NO:38), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:51), Figure 27 (SEQ ID NO:53), Figure 29 (SEQ ID NO:55), Figure 31 (SEQ ID NO:57), Figure 33 (SEQ ID NO:62), Figure 35 (SEQ ID NO:64), Figure 37 (SEQ ID NO:72), Figure 39 (SEQ ID NO:77), Figure 41 (SEQ ID NO:79), Figure 43 (SEQ ID NO:83), Figure 45 (SEQ ID NO:85), Figure 47 (SEQ ID NO:90), Figure 49 (SEQ ID NO:98), Figure 51 (SEQ ID NO:103), Figure 53 (SEQ ID NO:105), Figure 55 (SEQ ID NO:107), Figure 57 (SEQ ID NO:109), Figure 59 (SEQ

ID NO:114), Figure 61 (SEQ ID NO:120), Figure 63 (SEQ ID NO:125), Figure 65 (SEQ ID NO:127), Figures 67A-B (SEQ ID NO:129), Figure 69 (SEQ ID NO:131), Figure 71 (SEQ ID NO:136) and Figure 73 (SEQ ID NO:138).

4. Isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 10.

5. A vector comprising the nucleic acid of any one of Claims 1 to 4.

6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

7. A host cell comprising the vector of Claim 5.

8. The host cell of Claim 7, wherein said cell is a CHO cell.

9. The host cell of Claim 7, wherein said cell is an *E. coli*.

10. The host cell of Claim 7, wherein said cell is a yeast cell.

11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

12. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) and Figure 74 (SEQ ID NO:139).

13. An isolated polypeptide scoring at least 80% positives when compared to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) and Figure 74 (SEQ ID NO:139).

14. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 10.

15. A chimeric molecule comprising a polypeptide according to any one of Claims 12 to 14 fused to a heterologous amino acid sequence.

16. The chimeric molecule of Claim 15, wherein said heterologous amino acid sequence is an epitope tag sequence.

17. The chimeric molecule of Claim 15, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

18. An antibody which specifically binds to a polypeptide according to any one of Claims 12 to 14.

19. The antibody of Claim 18, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

20. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID

NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide;

(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), with its associated signal peptide; or

(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide.

21. An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID

NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide;

(b) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), with its associated signal peptide; or

(c) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide.

22. A method of detecting a polypeptide designated as A, B, C, D, E, F, G, H, or I in a sample suspected of containing an A, B, C, D, E, F, G, H, or I polypeptide, said method comprising contacting said sample with a polypeptide designated herein as J, K, L, M, N, O, P, Q, R, S or T and determining the formation of a A/J, B/K, C/L, C/M, C/N, C/J, D/O, E/P, F/Q, G/R, H/S or I/T polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of an A, B, C, D, E, F, G, H, or I polypeptide in said sample and wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a

PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.

23. The method according to Claim 22, wherein said sample comprises cells suspected of expressing said A, B, C, D, E, F, G, H, or I polypeptide.

24. The method according to Claim 22, wherein said J, K, L, M, N, O, P, Q, R, S or T polypeptide is labeled with a detectable label.

25. The method according to Claim 22, wherein said J, K, L, M, N, O, P, Q, R, S or T polypeptide is attached to a solid support.

26. A method of detecting a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T in a sample suspected of containing a J, K, L, M, N, O, P, Q, R, S or T polypeptide, said method comprising contacting said sample with a polypeptide designated herein as A, B, C, D, E, F, G, H, or I and determining the formation of a A/J, B/K, C/L, C/M, C/N, C/J, D/O, E/P, F/Q, G/R, H/S or I/T polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a J, K, L, M, N, O, P, Q, R, S or T polypeptide in said sample and wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.

27. The method according to Claim 26, wherein said sample comprises cells suspected of expressing said J, K, L, M, N, O, P, Q, R, S or T polypeptide.

28. The method according to Claim 26, wherein said A, B, C, D, E, F, G, H, or I polypeptide is labeled with a detectable label.

29. The method according to Claim 26, wherein said A, B, C, D, E, F, G, H, or I polypeptide is attached to a solid support.

30. A method of linking a bioactive molecule to a cell expressing a polypeptide designated as A, B, C, D, E, F, G, H, or I, said method comprising contacting said cell with a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T that is bound to said bioactive molecule and allowing said A, B, C, D, E, F, G, H, or I and said J, K, L, M, N, O, P, Q, R, S or T polypeptides to bind to one another, thereby linking said bioactive molecules to said cell, wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.

31. The method according to Claim 30, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

32. The method according to Claim 30, wherein said bioactive molecule causes the death of said cell.

33. A method of linking a bioactive molecule to a cell expressing a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T, said method comprising contacting said cell with a polypeptide designated as A, B, C, D, E, F, G, H, or I that is bound to said bioactive molecule and allowing said A, B, C, D, E, F, G, H, or I and said J, K, L, M, N, O, P, Q, R, S or T polypeptides to bind to one another, thereby linking said bioactive molecules to said cell, wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.

34. The method according to Claim 33, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

35. The method according to Claim 33, wherein said bioactive molecule causes the death of said cell.

36. A method of modulating at least one biological activity of a cell expressing a polypeptide designated as A, B, C, D, E, F, G, H, or I, said method comprising contacting said cell with a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T or an anti-A, B, C, D, E, F, G, H, or I polypeptide antibody, whereby said J, K, L, M, N, O, P, Q, R, S or T polypeptide or anti-A, B, C, D, E, F, G, H, or I polypeptide

antibody binds to said A, B, C, D, E, F, G, H, or I polypeptide, thereby modulating at least one biological activity of said cell.

37. The method according to Claim 36, wherein said cell is killed.

5 38. A method of modulating at least one biological activity of a cell expressing a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T, said method comprising contacting said cell with a polypeptide designated as A, B, C, D, E, F, G, H, or I or an anti-J, K, L, M, N, O, P, Q, R, S or T polypeptide antibody, whereby said anti-J, K, L, M, N, O, P, Q, R, S or T polypeptide antibody or A, B, C, D, E, F, G, H, or I polypeptide antibody binds to said J, K, L, M, N, O, P, Q, R, S or T polypeptide, thereby
10 modulating at least one biological activity of said cell.

39. The method according to Claim 36, wherein said cell is killed.